Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138245 | 0.84 | TAS2R14 (0.39) | BACE1POLBMAPTALOX5APFEN1 | |
| SCHEMBL28110043 | 0.83 | POLB (0.34) | BACE1KDM4EPOLBMAPTALOX5AP | |
| SCHEMBL21662129 | 0.81 | KIF11 (0.44) | KDM4EPOLBMAPTMAOBSMN1; SMN2 | |
| SCHEMBL6853258 | 0.81 | POLB (0.42) | BACE1KDM4EEPHX2SCN4APOLB | |
| SCHEMBL1474795 | 0.80 | TRPV1 (0.41) | KDM4EMAPTPRKDCPKMLMNA | |
| SCHEMBL398707 | 0.80 | BACE1 (0.38) | BACE1KDM4EEPHX2SCN4ACES2 | |
| SCHEMBL3033291 | 0.78 | CYP1A1 (0.46) | BACE1KDM4EPOLBMAPTCES2 | |
| SCHEMBL7254716 | 0.78 | POLB (0.43) | BACE1KDM4EEPHX2SCN4APOLB | |
| SCHEMBL472401 | 0.78 | CES2 (0.50) | BACE1KDM4EEPHX2SCN4APOLB | |
| SCHEMBL153434 | 0.78 | CYP1A1 (0.44) | BACE1KDM4EEPHX2SCN4APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250154172-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2025096589-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12258340-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| CN-116473965-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| CN-117229244-A | Orange ketone analogue and application thereof | 中国科学院新疆理化技术研究所 | 2023-12-15 | — | — | CN | disclosed |
| CN-117186045-A | Isobenzofuran-1 (3H) -ketone TREK-1 inhibitor, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2023-12-08 | — | — | CN | disclosed |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-02-09 | — | — | US | disclosed |
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1463714-A4 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-10-13 | — | — | US | disclosed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| US-5380865-A | Halogen substituents | MAY & BAKER LIMITED (GB) | 1995-01-10 | — | — | US | disclosed |
| US-5206257-A | Controlling plant nematodes, helminth, protozoa | MAY & BAKER LIMITED (GB) | 1993-04-27 | — | — | US | disclosed |
| EP-0283173-A1 | Pesticidal method using 2-phenylimidazole derivatives | RHONE-POULENC AGRICULTURE LIMITED (GB) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | BACE1 1269/4885KDM4E 4114/4885EPHX2 4360/4885 |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | BACE1 3887/4885KDM4E 147/4885EPHX2 3141/4885 |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | BACE1 1269/4885KDM4E 4114/4885EPHX2 4360/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | BACE1 2983/4885KDM4E 62/4885EPHX2 2763/4885 |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | BACE1 1021/4885KDM4E 4024/4885EPHX2 4355/4885 |
| US-20250154172-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | BACE1 2761/4885KDM4E 60/4885EPHX2 2915/4885 |
| US-12258340-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | BACE1 1686/4885KDM4E 2927/4885EPHX2 787/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | BACE1 2983/4885KDM4E 62/4885EPHX2 2763/4885 |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | BACE1 1269/4885KDM4E 4114/4885EPHX2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.